For the Quarter Ending September 2025
North America
• In United States, the Metoclopramide HCL Price Index rose in Q3 2025, driven by increasing production costs.
• Metoclopramide HCL production costs increased in Q3 2025, influenced by a 2.6% PPI rise in August 2025.
• The Metoclopramide HCL Demand Outlook was supported by a resurgence in the pharmaceutical sector in Q3 2025.
• The Metoclopramide HCL Price Forecast suggests continued upward pressure due to anticipated rising production costs.
• US natural gas prices strengthened throughout Q3 2025, impacting Metoclopramide HCL energy and feedstock expenses.
• A 3.0% CPI increase in September 2025 raised raw material and operational costs for Metoclopramide HCL production.
• A 4.3% unemployment rate in September 2025 supported patient access and affordability for Metoclopramide HCL.
• US chemical industry inventories shrank in Q3 2025, reflecting intensified destocking efforts by manufacturers.
Why did the price of Metoclopramide HCL change in September 2025 in North America?
• Production costs for Metoclopramide HCL increased due to a 2.6% PPI rise in August 2025.
• Rising natural gas prices in Q3 2025 contributed to higher energy and feedstock expenses.
• A 3.0% CPI increase in September 2025 elevated raw material and operational costs.
APAC
• In China, the Metoclopramide HCL Price Index fell quarter-over-quarter in Q3 2025, influenced by oversupply and deflationary pressures.
• Metoclopramide HCL production costs declined in September 2025, as producer prices fell 2.3% year-on-year.
• Metoclopramide HCL demand supported by 3.0% retail sales growth and 5.2% unemployment in September 2025.
• The Metoclopramide HCL price forecast indicates continued downward pressure due to broad chemical oversupply in Q3 2025.
• The Manufacturing Index contracted in September 2025, signaling economic slowdown impacting the supply chain.
• Robust pharmaceutical manufacturing growth in 2025, driven by aging population, supports Metoclopramide HCL demand.
• Persistent oversupply in the broader chemical sector in Q3 2025, from capacity additions, impacted market balance.
• General chemical feedstock costs remained steady in Q3 2025, despite ongoing high energy cost concerns.
• China's industrial production increased 6.5% year-on-year in September 2025, supporting the manufacturing base.
Why did the price of Metoclopramide HCL change in September 2025 in APAC?
• CPI fell 0.3% and PPI fell 2.3% in September 2025, exerting downward price pressure.
• Persistent oversupply in the broader chemical sector during Q3 2025, driven by capacity additions.
• Contracting Manufacturing Index and low consumer confidence (89.6) in September 2025 signaled caution.
Europe
• In Germany, the Metoclopramide HCL Price Index fell quarter-over-quarter in Q3 2025, influenced by declining producer prices.
• Elevated raw material costs and strengthened industrial electricity, influenced by 2.4% CPI, increased production.
• Producer prices for chemical and pharma declined -1.7% year-over-year in September 2025, easing input costs.
• Metoclopramide HCL demand outlook supported by aging population and increasing chronic diseases.
• German industrial production contracted -1.0% year-over-year in September 2025, impacting raw material.
• The Manufacturing Index contracted in Q3 2025, signaling a slowdown across German manufacturing.
• A low unemployment rate of 3.9% in September 2025 supported public healthcare funding and patient access.
• Retail sales grew modestly by 0.8% year-over-year in September 2025, indicating stable consumer spending.
• Consumer confidence at -23.6 in September 2025 indicated pessimistic sentiment, potentially constraining healthcare.
Why did the price of Metoclopramide HCL change in September 2025 in Europe?
• Producer prices for chemical and pharma declined -1.7% year-over-year in Q3 2025, reducing input costs.
• Elevated chemical raw material costs and strengthened industrial electricity prices increased production expenses.
• German chemical industry overcapacities and weakening export demand created competitive pricing.
For the Quarter Ending June 2023
North America
U.S. metoclopramide hydrochloride prices showed a mixed trend in the second quarter of 2023. Prices increased in May slightly by 1.18% because of increased demand from end-users coupled with inventory replenishment activities with fresh stock, which kept the market on the north side. The Manufacturing PMI (Purchasing Managers' Index) came in at 48.4 in May, demonstrating a slowdown in the U.S. manufacturing sector.
This shows that the supply of manufacturers and suppliers has been constrained due to reduced business activity. But consumer demand remained strong, leading to increased metoclopramide hydrochloride prices in May. In contrast, prices fell 4.23% in June compared to May due to exceptionally sluggish offtakes in end-user industries.
Domestic suppliers have abundant Metoclopramide Hydrochloride in their inventory, resulting in continuously falling costs in the domestic market. Additionally, high-interest rates by Federal Reserve interest have reduced the demand for metoclopramide hydrochloride in the market, further supporting the bearish trend. Also, the U.S. dollar appreciated against Chinese yuan in June, increasing imports in the U.S. market, further putting downward pressure on the prices of Metoclopramide HCL.
Asia Pacific
Prices for metoclopramide hydrochloride in China showed mixed trends in the second quarter. Metoclopramide hydrochloride prices rose 1.21% in May, contrasting with April levels due to consistent demand in the domestic market and ongoing operational activity. China's Purchasing Managers Index (PMI) fell to 48.8 in May from 49.2 in April, signaling a slowdown in factory activity, leading to fewer inventories among market manufacturers and suppliers to fulfill the strong demand in the market, pushing the prices upward. In contrast, metoclopramide hydrochloride prices fell 3.21% in June from May as new order follow-up and consumer purchasing activity slowed. The official manufacturing Purchasing Managers Index (PMI) rose to 49.0 in June from 48.8 in the previous month, signaling a slowdown in manufacturing activity. Production decreased due to sluggish end-user demand. However, prices are kept low as market participants hold sufficient inventory to meet existing market demand. Additionally, Chinese exports fell by 12.4% in June, leading to increased availability of metoclopramide hydrochloride on the Chinese market, supporting the downward trend in prices.
Europe
In Germany, the situation of metoclopramide hydrochloride showed a mixed trend throughout the second quarter. Prices rose slightly in May to 1.19% from April, then fell to 4.38% in June. Prices rose in May due to limited stockpiles among traders and suppliers, coupled with increased demand from end-user industries. The manufacturing Purchasing Managers' Index (PMI) for Germany fell to 43.2 in May from 44.5 in April, reflecting weaker business activity, lower inventories among market participants with delays in shipments to meet demand, leading to increase in metoclopramide hydrochloride prices. In June, the German economy was hit by rising inflation and an interest rate hike by the European Central Bank, leading to higher food and energy prices. This has increased the cost of living and reduced consumer purchasing activity, supporting the downward trend in the price of metoclopramide hydrochloride. Furthermore, the appreciation of the Euro against the U.S. Dollar in June made imports cheaper and also increased the supply of metoclopramide hydrochloride in the German market. This puts further downward pressure on the prices.
For the Quarter Ending March 2023
North America
The first quarter of 2023 saw an overall stable trajectory for Metoclopramide HCL API in the North American region. Due to increasing production activities and strong manufacturing rates, prices were noted to be on the higher side at the start of January. The decision by retailers to add additional inventory to their stockpiles also contributed to the upward pricing trend. As soon as February began with low to moderate demand dynamics, prices began to decline. Reduced freight fees were another factor contributing to the favorable market circumstances. Ease in a prolonged, severe labor shortage, inflation, and energy cost further supported the decreased trajectory. The prices were evaluated and accessed at USD 132425/CFR Houston at the termination of Q1 2023 with an average quarterly inclination of 0.81%.
Asia
Metoclopramide HCL market prices showcased fluctuating trajectory in the first quarter of 2023. At the end of Q1 2023, the prices were assessed at USD 130325/Fob Shanghai, with an average quarterly declination of 1.35%. With the commencement of January, the prices were recorded to be on the higher side on the back of increased production activities and high manufacturing rates. Also, the merchants decided to replenish their inventories with new stock, supporting the positive price trend. The prices decreased as soon as February started with low to moderate demand dynamics. Also, reduced freight charges also added to the favorable market conditions. Additionally, When the Covid-policy and supply chain issues were resolved, the market situation in China improved.
Europe
The first quarter of 2023 saw a firm market situation for Metoclopramide HCL API in the European region. With an average quarterly inclination of 0.15%, the prices of Metoclopramide HCL were accessed at USD 136380/MT CFR Hamburg. With the easing of inflation, the drop in energy prices, and the reopening of the Chinese economy, Germany's internal economic recovery has started. As a result of the flow of pharmaceutical items from East Asia having now somewhat stabilized, which benefits the end-user sector, supply chains in Europe are already much less congested. Later, the prices dropped considerably as the market for Metoclopramide HCL was also restrained by a drop in domestic inquiries. Also, the market was kept calm by the resumption of higher trade flows in Europe. Decreased freight charges also influenced the market prices.
For the Quarter Ending December 2022
North America
The fourth quarter of 2022 will see a decline in the price of Metoclopramide HCL as a result of minimal to non-existent demand from the downstream pharmaceutical business and logistical ease. Low sea freight costs have an impact on the market for Metoclopramide HCL in the North American continent. The market remained sluggish due to reduced port congestion and an efficient supply network. Customers were reluctant to place substantial purchases due to rising inflation, forcing merchants to cut their quotations to increase inquiries. Low input costs and decreased Benzoic acid prices have a negative effect on the cost of Metoclopramide HCL. The prices were evaluated and accessed at USD 127250/CFR Houston at the termination of Q4 2022 with an average quarterly declination of 0.56%.
Asia
Metoclopramide HCL market prices fell significantly in the fourth quarter of 2022 because of the decline in demand from the downstream pharmaceutical industry. At the end of Q4 2022, the prices were assessed at USD 125250/Fob Shanghai, with an average quarterly declination of 2.25%. The ministry also made the decision to reduce the cost of generic medications in Asia in order to retain their accessibility and availability to customers. With reduced input costs and the lowering of raw materials, Benzoic acid prices also showed a downward trend globally, which had a negative impact on the pricing of Metoclopramide HCL. Further, low demand and fewer inquiries from the international market kept the market situation weak.
Europe
The fourth quarter of 2022 saw deflation in the European market condition for Metoclopramide HCL. With an average quarterly decline of 0.67%, the prices of Metoclopramide HCL were found at USD 147200/MT CFR Hamburg. The market showed a weak market situation with ease in the shipments and transportation activities. Additionally, relief in port congestion at Europe's key ports kept the market weak by enabling an unimpeded supply chain. The prices increased marginally in November due to a sizable order to maintain the domestic region's well-stocked inventories. The weak market trend was also maintained by a decrease in inflation around the conclusion of Q4. Low input costs and falling benzoic acid prices have a detrimental impact on the cost of Metoclopramide HCL.
